Infante JF, Sifontes S, Arencibia DF, Hernández T, Fariñas M, Pérez O

Idioma: Ingles.
Referencias bibliográficas: 22
Paginas: 1-5
Archivo PDF: 327.77 Kb.

RESUMEN

El cocleato AFCo1, derivado de un proteoliposoma de Neisseria meningitidis B, es un nuevo y potente adyuvante vacunal. En el presente trabajo se evaluó la seguridad del AFCo1 mediante un estudio de dosis repetida en ratas Sprague Dawley. Los animales se agruparon en: tratados con AFCo1, placebo y control. Se les administraron cuatro dosis de 100 μL durante 5 días por vía intranasal. Se monitoreo el peso corporal, consumo de agua y alimento y los síntomas clínicos; así como estudios hematológicos y bioquímicos. Las ratas se sacrificaron a los 3, 14 y 28 días después de la última inoculación y se les realizó, además, pruebas anatomopatológicas. Los síntomas clínicos, el consumo de agua y alimento y el peso corporal no mostraron diferencias de relevancia toxicológica. Los cambios histológicos encontrados fueron leves y con frecuencias similares en los tres grupos. Por lo que se concluyó que el adyuvante AFCo1 nasal es potencialmente no tóxico para uso en humanos, por la ausencia de signos locales y sistémicos de toxicidad en las ratas Sprague Dawley.

REFERENCIAS (EN ESTE ARTÍCULO)

1. McGhee JR, Kiyono H. Mucosal immunology. In: Paul WE, editor. Fundamental Immunology. (Vol. 909). San Diego: Academic Press; 1998. p. 167-79.

2. Acevedo R, Gil D, Del Campo J, Bracho G, Valdez Y, Pérez O. The adjuvant potential of synthetic alkylglycerols. Vaccines 2006; 24(Suppl 2):32-3.

3. Yamamoto N, Claire S, Homma JR, Ngwenga BZ. Activation of mouse macrophages by alkylglycerols. Cancer Res 1988; 48(21):6044-9.

4. Lycke N. From toxin to adjuvant: the rational design of a vaccine adjuvant vector. CTA1-DD/ISCOM. Cell Microbiol 2004;6(1):23- 32.

5. Pérez O, Bracho G, Lastre M, Mora N, del Campo J, Gil D, et al. Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogenassociated molecular pattern. Immunol Cell Biol 2004;82(6):603-10.

6. del Campo J, Lastre M, Bracho G, Rodríguez T, Gil D, Zayas C, et al. Immunological evaluation of bacterial derived Cochleate and proteoliposome as mucosal adjuvants. Vaccine 2006; 24 (Suppl 2):S50-1. Table 2. Repeated dose toxicity test: frequency of lesions in rats 3 and 14 days after the last dose. Fig. 1. Lymph node of female placebo rat in the repeated dose toxicity test sacrificed 3 days after the last inoculation. Secondary follicles in the subcortical and paracortical areas (arrows) were observed. H.E 120X. Fig. 2. Secondary follicle with apoptotic lymphocytes (arrows) in the regional lymph node, single dose toxicity test, female rat inoculated with AFCo1. H.E 220X.

7. Canadian Council on Animal Care. Laboratory rats. Guide to the care and use of experimental animals. (Vol. 2). Ottawa, Ontario: Canadian Council on Animal Care; 1993.

8. ISO. Norm Part 10: Test for irritation and delayed hypersensitivity. Biological Evaluation of Medical Devises. ISO 10993/10; 2002.

9. Sutkowski EM. Non Clinical Safety Assessment of Preventive Vaccines: the FDA Perspective. In: Proceeding of the Workshop on Non Clinical Safety Evaluation of Preventive Vaccines: Recent Advances and Regulatory Considerations. Vol I. Washington, DC; 2002. p. 203-82.

10. Ledwith B. The Relevance of Animal Studies for Non-Clinical Safety Assessment of Vaccines In: Proceeding of the Workshop on Non Clinical Safety Assessment of Preventive Vaccines: Recent Advances and Regulatory Considerations Vol I. Washington, D.C; 2002.p. 546-666.

11. World Health Organization. Guidelines on Nonclinical Assessment of Vaccines. WHO Technical Report Series. Adopted by the 54th meeting of the WHO Expert Committee on Biological Standardization, No. 54, 21, Geneva: WHO;2003. p. 37-48.

12. Sosa E, Sifontes S, Infante JF, Díaz D, López Y, Pérez V, et al. Local tolerance of vax-Tyvi® vaccine in Sprague Dawley Rats. VacciMonitor 2005;14(1):21-7.

13. Infante JF, Sifontes S, Álvarez E, González M, Pérez V. Sosa E, et al. Single dose toxicity and local tolerance evaluation of vax-SPIRAL® vaccine in Sprague Dawley rats. VacciMonitor 2004;13(2):11-6.

14. Infante JF, Sifontes S, Pérez V, Bracho G, Hernández T, Zayas C, et al. Study of immunogenicity and local toxicity of Neisseria meningitidis cochleates in Sprague Dawley rats. VacciMonitor 2009;18(1):1-7.

15. Sifontes S, Infante JF, Díaz D, López Y, Pérez M, Sosa E, et al. Repeated dose toxicity study of life attenuated oral Cholera vaccine in Sprague Dawley rats. Arch. Med. Res 2009;40:527- 35.

16. Pritchett KR, Coming BF. Biology and Medicine of rats: In: Rueter JD and Suckow MA, editores. Laboratory Medicine and Management. Ithaca NY: International Veterinary Information Service; 2004. Disponible en: http://www.ivis.org.

17. Martín E, Nicolás GM. Nasal mucilliary clearance as a factor in nasal drug delivery. Advanced Drug Delivery Reviews 1998;29:865-85.

18. Finn J, Espen S, Baekkvold H, Carlsen I, Farstad N, Soler D, et al. Regional induction of adhesion molecules and chemokine receptors explains disparate homing of human B cells to systemic and mucosal effector sites: dispersion from tonsil. Blood 2005;106:503-600.

19. Wlaf JL. The Membranous epithelial (M) cell and the mucosal immune system. Annu Rev Med 1984;35:95-112.

20. López Y, Infante JF, Sifontes S, Díaz D, Pérez V, Año G, et al. Pharmacology and toxicology of an oral tablet whole-cell inactivated cholera vaccine in Sprague Dawley rats. Vaccine 2011;9:3596-9.

21. López Y, Sifontes S, Infante JF, Díaz D, Obaya M, Álvarez E, et al. Evaluation of toxicity by single dose of the Diphtheria- Tetanus Vaccine in Sprague Dawley rats. VacciMonitor 2005;14(2):1-6.

22. Kuck D, Lau T, Leuchs B, Kern A, MüllerM, Gissmann L, et al. Intranasal Vaccination with Recombinant Adeno-Associated Virus Type 5 against Human papillomavirus Type 16 L1. Journal of Virology 2006;80:2621-30.